---
title: 'The Niche Episode 034 – Genentech, GSK, BMS, Cassava, Sanofi, Hyperfine'
type: 'episode'
url: 'https://doc.social/episodes/the-niche-episode-034-genentech-gsk-bms-cassava-sanofi-hyperfine'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2021-02-15'
audio: 'unavailable — the host retired the file'
---

# The Niche Episode 034 – Genentech, GSK, BMS, Cassava, Sanofi, Hyperfine

Genentech’s next tech, GSK divests to invest, Bristol Myers Squibb checks oncology, Cassava Sciences raises capital, Libtayo gets expanded FDA approval, and Hyperfine turns on hyperdrive. Sponsorshttps://www.thescopemethod.comStory Referenc…

## Summary

Genentech’s next tech, GSK divests to invest, Bristol Myers Squibb checks oncology, Cassava Sciences raises capital, Libtayo gets expanded FDA approval, and Hyperfine turns on hyperdrive.

**Sponsors
**[https://www.thescopemethod.com](https://www.thescopemethod.com)

**Story References
**[https://tinyurl.com/Niche-34-1](https://tinyurl.com/Niche-34-1)
[https://tinyurl.com/Niche-34-2](https://tinyurl.com/Niche-34-2)
[https://tinyurl.com/Niche-34-3](https://tinyurl.com/Niche-34-3)
[https://tinyurl.com/Niche-34-4](https://tinyurl.com/Niche-34-4)
[https://tinyurl.com/Niche-34-5](https://tinyurl.com/Niche-34-5)
[https://tinyurl.com/Niche-34-6](https://tinyurl.com/Niche-34-6)

**Music by Luke Goodson
**[https://www.soundcloud.com/lukegoodson](https://www.soundcloud.com/lukegoodson)

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.